Curative Biotechnology Inc logo

CUBT - Curative Biotechnology Inc News Story

$0.111 0.0  6.4%

Last Trade - 15/10/21

Sector
Healthcare
Size
Micro Cap
Market Cap £43.4m
Enterprise Value £43.8m
Revenue £193k
Position in Universe th / 7247

Curative Biotechnology, Inc. Appoints Marc Drimer, CPA to Board of Directors as Independent Director and Chairman of Audit Committee

Thu 15th July, 2021 3:00pm
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20210715:nGNX9Xv3YW&default-theme=true


Boca Raton, FL, July 15, 2021 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc.
(OTC: CUBT) (“Curative Biotech” or the “Company”), a development stage
biomedical company focused on novel therapies for rare diseases, announced
today that Marc Drimer, CPA has joined its Board of Directors as an
independent director and Chairman of the Audit Committee. Mr. Drimer has over
35 years of experience in all areas of corporate governance, compliance and
operations in the financial services industry. He has held management
positions in London and Geneva serving as Controller of Hertz Europe and
Allied Maintenance. He is a graduate of Brooklyn College with a BS in
Accounting and holds an MBA in Finance from New York University Graduate
School of Business.

Mr. Drimer is currently the CFO for Lampert Capital Markets, Inc. responsible
for all financial and operational aspects of the firm. He is the Financial and
Operations principal as well as the Options and Municipal Bond principal. He
has acted in a principal capacity as both a CEO and CFO for a number of
brokerage firms and investment banks, responsible for the origination and
syndication of numerous private placements and initial public offerings in a
broad range of industries. He holds the Series 4, 7, 24, 27, 53, 63 and 79
licenses.

Chairman and President Paul M. Michaels said “Adding Marc Drimer to our
Board as an independent director is another major milestone for Curative
Biotech. Marc has decades of broad experience at the highest levels in the
financial services industry and is known for his professionalism and business
acumen. We are excited and eager to begin working with Marc in developing
capital market options and potential partnerships as the Company advances its
therapeutic pipeline.”

About Curative Biotechnology, Inc. http://CurativeBiotech.com
Curative Biotechnology is a development stage biomedical company focusing on
novel treatments for rare diseases. Curative Biotech is focused on therapies
with potentially accelerated development paths as a result of either the
disease, the nature of the therapeutic itself, or the stage of clinical
development. At the heart of the Company is a clinical product development
engine that rests on our unique S.O.A.R. filter (Science, Opportunity,
Acceleration, Rare Disease.) At Curative Biotech, we envision a world where
all patients have a therapeutic option.

Forward-Looking Statements

This press release contains “forward-looking statements” within the
meaning of Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934. CUBT is not yet generating
revenues. Although forward-looking statements in this release reflect the good
faith judgment of management, forward-looking statements are inherently
subjected to known, unknown risks and uncertainties that may cause
actual results to be materially different from those discussed in these
forward-looking statements, including but not limited our ability to generate
sufficient market acceptance for our products and services, our ability to
generate sufficient operating cash flow, and general economic conditions.
Readers are urged to carefully review and consider the various disclosures
made by us in our reports filed with OTC Markets from time to time which
attempt to advise interested parties of the risks and factors that may affect
our business, financial condition, results of operation and cash flows. If
one or more of these risks or uncertainties materialize, or if the underlying
assumptions prove incorrect, our actual results may vary materially from those
expected or projected. Readers are urged not to place undue reliance on these
forward-looking statements, which speak only as of the date of this release.
We assume no obligation to update any forward-looking statements in order to
reflect any event or circumstance that may arise after the date of this
release.

Contact:
Steve Chizzik
Investor Relations
Curative Biotech (CUBT) 
201-454-5845
ir@curativebiotech.com
SOURCE: Curative Biotechnology, Inc.


(https://www.globenewswire.com/NewsRoom/AttachmentNg/cd81c045-6ab2-4761-b613-1948a7e20526)



GlobeNewswire, Inc. 2021
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.